RSS

Besponsa

The US Food and Drug Administration (FDA) has approved a targeted therapy, Besponsa (inotuzumab ozogamicin), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). more

News